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A b s t r a c t
Since the cryoballoon was introduced into clinical practice, approximately half a million patients have undergone a pulmonary 
vein isolation (PVI) using this tool throughout the world. This single-shot technique makes the pulmonary vein isolation proce-
dure easier and has the potential to expand access to the interventional treatment of atrial fibrillation (AF), eventually leading to 
a reduction of the AF-related disease burden. Several studies and metanalyses have assessed the acute and long-term efficacy of 
cryoballoon-based PVI. The reported success rate of PV isolation during the procedure is about 98%. Despite this, the long-term 
effectiveness of the procedure (AF free survival) assessed at 1 year after the ablation is in the range of 70–82%. The AF-free survival 
rate significantly depends on the clinical characteristics of the studied group and the presence of risk factors, especially the type of 
AF (paroxysmal vs. persistent), LA size and the presence of heart failure. For a safe and effective procedure the electrophysiologist 
should be aware of all minute details of the procedure including several tricks developed by the most experienced operators and 
the pre-procedural and post-procedural management recommendations. Detailed knowledge of complications of cryoballoon (CB)-
based ablation is mandatory. This review concentrates on the practical aspects and recommendations for a cryoballoon ablation 
procedure. The review is based on the authors’ experience, including 800 procedures performed over 11 years with a low complica-
tion rate, and is presented within the context of the literature. 
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Introduction
There has been substantial progress in the diagnosis 
and treatment of atrial fibrillation (AF) over the last two 
decades. During that time catheter-based pulmonary 
vein (PV) isolation became the most effective method 
of AF treatment. However, since AF is the most common 
sustained arrhythmia and a significant cause of morbid-
ity and mortality generating high costs for healthcare, 
there was a need for a more streamlined, more standard-
ized procedure and with a  steeper learning curve than 
the classic point-by-point radiofrequency (RF) catheter 
based PV isolation procedure. That demand was met by 
the development of several single-shot techniques [1]. 
The most successful of these was the cryoballoon (CB) 
ablation method, with already over half a million of pa-
tients having undergone that procedure. The less com-
monly used single-shot tools are the ‘hot balloon’ and 
the pulmonary vein ablation catheter (PVAC). Single-shot 
techniques make the PV isolation procedure easier and 
have the potential to expand access to the interventional 
treatment of AF, eventually leading to a reduction of the 
AF-related disease burden. Clinical equivalency, in terms 
of clinical outcome, between CB ablation and RF abla-
tion was documented by the ‘Fire and Ice’ trial and other 
studies [2]. In this article we will review and summarize 
the current knowledge regarding outcomes of cryobal-
loon ablation and provide a practical, ‘hands-on’ review 
of the technique on the basis of the literature and our 
experience with over 800 cryoballoon procedures per-
formed during the last 11 years. 
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Cryo – an old new energy source 
The physical mechanism responsible for inducing 
freezing in tissues is based on the Joule-Thomson effect: 
the temperature decline of an expanding gas when it is 
forced to pass through a valve where it loses pressure. 
An important milestone in the practical application of 
cryoenergy was the invention of a closed cryoprobe with 
continuous flow of liquid nitrous oxide by New York City 
neurosurgeon Irving Cooper in 1961. The first cardiac ap-
plication of such a cryoprobe, by John Gallagher at Duke 
University in the USA, was for intraoperative ablation 
of accessory pathways and the atrioventricular node in 
1977. The introduction of steerable percutaneous cryoca-
theters (2001) and cryoballoons (2006) made cryoenergy 
available for all interventional electrophysiologists.
The aim of cryoablation is to selectively destroy the 
targeted tissue in a chosen area using low temperature. 
The main mechanisms of low temperature induced cel-
lular damage result from a combination of direct cellu-
lar failure related to the harmful effects of ice crystal 
formation during hypothermia and ischemic cell death 
attributable to microcirculatory damage and the follow-
ing vascular stasis during thawing. The current under-
standing of this complex mechanism divides it into the 
following stages: (1) freeze and thaw, (2) hemorrhage 
and inflammation, and (3) replacement fibrosis. In the 
first phase hypothermia leads to stiffening of cardiac 
myocytes, destruction of ion pumps and the intracellular 
pH becomes more acidic. Persistence of these changes 
depends on the minimal achieved temperature and the 
duration of cryoapplication – the shorter the exposure to 
hypothermic conditions, the more rapidly cells recover. 
This property of cryoenergy has very important clinical 
implications – it permit the functional assessment of 
the chosen ablation areas (cryomapping) without per-
manent cellular injury. Continuation of freezing results 
in formation of ice crystals (a  hallmark of irreversible 
tissue destruction), firstly in the extracellular matrix and 
later intracellularly. The density of ice crystals and their 
dimension depend on distance to the cryocatheter, the 
achieved local temperature and the rate of cooling. Intra-
cellular ice crystals cause progressive damage of intra-
cellular organelles when extracellular crystals cause the 
extracellular space to become hypertonic, subsequent-
ly leading to cell shrinkage and rendering the intracel-
lular space hyperosmotic and acidic. It finally results in 
damage of enzymes, protein impairment and ultimately 
rupture of the cell membrane. Freezing also negatively 
affects microcirculation which leads to (A) hyperemia, 
(B) interstitial edema and (C) microthrombosis, which 
eventually leads to tissue ischemia. After freezing is com-
pleted, the tissue slowly, passively returns to the tem-
perature of the body – known as the thawing effect. In 
this phase of cryoablation, intracellular crystals are fused 
into larger masses, further extending the cellular dam-
age. In the second phase water migrates out of the endo-
thelial cells to re-establish the osmotic equilibrium that 
was interrupted earlier. This causes a further increase of 
intracellular osmotic pressure and can lead to further cell 
membrane failure. Over time a restoration of microcircu-
lation to the previously frozen area occurs, resulting in 
edema and further ischemic necrosis. In the last stage, 
which occurs weeks after the procedure, the final lesion 
is created due to fibrosis and apoptosis of cells close to 
the borders of frozen tissue. 
Size of final lesions is related to minimum achieved 
temperature, probe size and contact area with target 
tissue, duration of application(s), number of repeated 
freeze/thaw cycles, rate of freezing, contact pressure and 
the local blood flow. The safety profile of this technique 
is well documented. The unique feature of cryoener-
gy-based ablation is cryomapping: in the temperature 
range of 0 to –30°C conduction in the cardiac tissues 
reversibly slows down and is eventually blocked while 
permanent lesions are created when the temperatures 
drops below –60 to –80°C. In contrast to the RF ener-
gy, the cryothermal energy application results in discrete 
homogeneous lesions that are clearly demarcated, with 
compact areas of fibrotic tissue, and a preserved tissue 
matrix with alive endothelial cell layers.
Cryoballoon technology
The Arctic Front system (Medtronic, Minneapolis, MN, 
USA) consists of the CryoConsole that provides the cool-
ant and the electronic control systems, a 15F steerable 
sheath (FlexCath) and the 10.5-F balloon catheters avail-
able in two sizes (23 mm and 28 mm). The first gener-
ation of cryoballoon (CB1) was introduced in Europe in 
2006 and in the USA in 2011. The CB1 had four cooling 
jets with a distance of 7 mm to the balloon tip, resulting 
in a limited equatorial freezing region that might result 
in an ineffective circular lesion around the PVs. The sec-
ond-generation cryoballoon (CB2), approved by the FDA 
in 2012, was produced on a similar platform as its pre-
decessor, but with a shorter distance from the refriger-
ating jets to the balloon tip (2.5 mm), and the number 
of refrigerant jet ports has been doubled. With these 
improvements, the CB-2 can create a  wider and more 
homogeneous lesion, extending from the equator up to 
the distal tip. These modifications led to better short-
term and long-term success rates in terms of freedom 
from AF. A central lumen present in these balloon cath-
eters permits introduction of a guidewire for positioning 
or introduction of a special circular diagnostic mapping 
catheter for monitoring of PV potentials and positioning 
as well as the injection of contrast. To facilitate PV po-
tential recording, the third generation cryoballoon (CB-3) 
was released in 2015 with a 40% shorter tip compared 
to its predecessor – but because of technical issues with 
the temperature probe and some dislodgement issues it 
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was withdrawn from the market. The above-mentioned 
issues were solved and the fourth generation CB (CB-4) 
was released in October 2018.
A competing cryoballoon system, the POLAR X (Boston 
Scientific, Marlborough, MA, USA), was recently released. 
It was very similar in design and working principles to 
the Arctic Front system although minor improvements/
modifications were claimed: 1) a more uniform pressure 
inside the cryoballoon during inflation and the ablation 
phase potentially protecting from dislodgment/pop-out 
caused by the balloon expansion, 2) a tighter bend radi-
us (155º) of the steerable sheath that can improve cryo-
balloon positioning and access to the inferior pulmonary 
veins, 3) more versatile cryoconsole that allows optional 
phrenic nerve and esophageal temperature monitoring, 
automation of patient data collection and retrieval and 
ability to program customized ablation quality indicators 
and timers, and 4) the cryoconsole allows single operator 
technique since the physician handling the cryoballoon 
can inflate, ablate, mark isolation, and stop therapy by 
using a foot pedal. However, the larger outer sheath di-
ameter of the POLAR X than the ArcticFront (15.9 vs. 15 Fr) 
is potentially disadvantageous.
Pre-procedural considerations and patient 
management
Indications
European Guidelines 2020 concerning management 
of patients with atrial fibrillation recommend performing 
PVI in patients with symptoms after ineffectiveness or 
intolerance of pharmacological treatment with at least 
one antiarrhythmic drug from class I or III. This is a class I 
recommendation for patients with paroxysmal and per-
sistent AF regardless of the presence of major risk factors 
for recurrence of AF. These guidelines also recommend 
performing PV isolation already after failed b-blocker 
treatment (IIa) or as a first-step treatment for patients 
with paroxysmal (IIa) and persistent (IIb) AF, considering 
in the decision process the patient’s preferences, poten-
tial benefits, and risks. Importantly, PV isolation is recom-
mended as a first-line therapy to reverse LV dysfunction 
in AF patients when tachycardia-induced cardiomyopathy 
is highly probable (class I) and also as a strategy to avoid 
pacemaker implantation (IIa) in patients with AF-related 
bradycardia or symptomatic pre-automaticity pause af-
ter AF conversion (i.e. sick sinus syndrome). 
The main goals and benefits of PV isolation are the 
reduction of arrhythmia-related symptoms and improve-
ment in quality of life. Among asymptomatic patients PV 
isolation could by conducted after detailed discussion 
and consideration of the pros and cons, as there are no 
randomized trials to ensure mortality benefits in AF pa-
tients without heart failure. However, pathophysiological 
reasoning and some studies point to decreased mortality, 
stroke and heart failure rates after AF ablation [3–5].
Risk of AF recurrence after ablation
To facilitate patient counselling and selection for CB 
ablation several risk scales that assess the risk of AF re-
currence after CB ablation were proposed [6]. The major 
risk factors connected with AF recurrence include per-
sistent AF type, obesity, enlargement of the left atrium 
and reduced ejection fraction of the left ventricle. These 
risk scores have some limitations. Firstly, they are dif-
ficult to use in clinical practice because of a  lot of in-
cluded components, sometimes based on hard to obtain 
data. Secondly, application of these risk scores in differ-
ent populations provided divergent results, probably due 
to the inclusion of a number of risk factors that were not 
universal but population/operator/center dependent. To 
address these limitations our center developed a simpli-
fied tool based on only two universally validated, easily 
available and strong risk factors: AF type and left atrial 
(LA) size > 45 mm – named the “0-1-2 PL score”. This 
score had higher predictive power, as assessed by area 
under the curve, than other much more complicated 
scores that were validated on non-Polish populations (in 
press). 
Anticoagulation
Patients with risk factors for stroke should take ade-
quate anticoagulation for at least 3 weeks directly before 
the procedure (class I) – alternatively, transesophageal 
echocardiography could be performed to exclude the 
presence of thrombi in the LA (IIa). The 2020 ESC guide-
lines recommend not interrupting the oral anticoagulant 
therapy before ablation – as such a strategy was used in 
trials that compared warfarin with novel anticoagulants. 
However, other recent guidelines (2017 HRS/EHRA Calk-
ins et al.) considered that it is reasonable to hold one to 
two doses of novel oral anticoagulant prior to AF ablation 
with re-initiation after ablation. We believe that it is un-
reasonable to perform ablation on an active oral anticoag-
ulant without immediate access to a reversible agent and 
that the local anticoagulant strategy should be monitored 
with local outcomes/complication rather than blindly 
rely on data from trials performed in different centers/
populations. In our center we follow the strategy of post-
poning the morning dose of any oral anticoagulant, with 
the re-initiation on the same day, 6 h after the vascular 
sheaths are removed/hemostasis achieved. No peripro-
cedural strokes were observed in our center over several 
years when such a strategy of minimal interruption was 
followed. 
The cryoballoon ablation procedure
Access
Femoral access is obtained in a  typical fashion. To 
minimize the local trauma and the risk of arterial punc-
ture we probe for the femoral vein by aspiration during 
injection of local anesthesia via a thin needle (outer di-
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ameter 0.8 mm). This method can precisely pinpoint the 
location and depth of the femoral vein as the thin needle 
does not obliterate the vein lumen when puncturing the 
vein wall. In difficult cases ultrasound is used to visual-
ize the femoral vein and Valsalva maneuvers to increase 
the size of the vein. We perform three venous punctures: 
one for the transseptal sheath and two to introduce the 
His catheter and steerable coronary sinus (CS) diagnostic 
multipolar catheter. Diagnostic catheters facilitate trans-
septal puncture by providing anatomical landmarks and 
are subsequently used for pacing maneuvers to confirm 
PV isolation, for ventricular pacing during bradycardia 
and for phrenic nerve pacing. 
Transseptal puncture is performed using the electro-
physiological approach, SL-1 sheath and the Brocken-
brough (BRK-1) needle. The whole assembly/needle tip 
should be oriented medially and posteriorly. The orien-
tation of the transseptal needle is adjusted according to 
the coronary sinus catheter/mitral annulus position by 
keeping the needle indicator pointing at the 4 o’clock 
(usually) to even at the 8 o’clock direction (in severely 
rotated hearts). For this the right anterior oblique view 
can be used as it helps to locate the dilator tip posterior 
to the site of the His catheter and posterior and parallel 
to the CS catheter. In the left anterior oblique (LAO) view 
the tip of the dilator should be well above the CS cath-
eter. Contrast injection (the septal staining technique) is 
occasionally used to visualize the interatrial septum. In 
difficult cases, the interatrial septum should be visual-
ized with intracardiac or transesophageal echocardiogra-
phy to increase the safety of the puncture – guided then 
by the tenting sign. For fossa ovalis localization the whole 
assembly is slowly withdrawn under fluoroscopy in the 
LAO 30° projection until two jumps of the catheter tip are 
observed, one from the superior vena cava to the right 
atrium (often very minimal in LAO) and the other (usually 
very obvious) into the fossa ovalis. We do not follow the 
recommendations for low fossa ovalis puncture as in our 
experience it makes access to the PV more difficult. The 
interatrial septum is then punctured by advancing the 
needle. At this point, the blood is withdrawn for initial 
confirmation of LA access. We do not use pressure mon-
itors but rely on fluoroscopic visualization of contrast in-
jected through the needle to confirm access to the LA. 
In case of doubt/poor visibility, coronary angioplasty or 
another 0.014” guidewire can be introduced through the 
needle and positioned in one of the PVs to confirm that 
the appropriate structure was accessed. The introducer 
together with the SL-1 sheath is then inserted over the 
needle into the LA. After this the SL-1 sheath is immedi-
ately replaced with a stiff 0.035” guide wire, positioned 
in one of the left-sided PVs. A heparin bolus of 10 000– 
16 000 U is administered, aiming for an activated clotting 
time of 350–400 s; this should be performed immediate-
ly after puncture or preferably before puncture [7].
Sedation and analgesia
Shortly before the procedure intravenous acetamin-
ophen (1000 mg) is administered to reduce the need 
for opioids. During the procedure, after the transseptal 
puncture, intravenous boluses of midazolam (2.5 mg) 
and fentanyl (0.05 mg) are used for pain/anxiety control. 
The procedure is usually well tolerated.
Engagement and occlusion of the veins
Engagement of the left-sided PVs is performed in LAO 
30–40° while right-sided PVs are engaged and ablated in 
the postero-anterior view and occasionally in the shallow 
RAO view. We use the dedicated intraluminal circular map-
ping catheter (Achieve catheter) to intubate all PVs starting 
with the left superior or the left inferior vein. The inferior 
PVs are located posterior and inferior to the superior PVs; 
therefore, once a superior or an inferior vein is intubated 
this directs the rotation and flexing of the Flexcath sheath 
to intubate the other. To prevent LA trauma/perforation by 
the stiff tip of the CB catheter or the Flexcath sheath the 
soft-tipped mapping catheter should always be exposed to 
lead the CB catheter. For de novo PV isolation procedure 
we do not recommend any preprocedural visualization 
of the LA anatomy or intraprocedural visualization of the 
veins using angiography as this is very rarely useful and 
has unproven outcome benefits. In the vast majority of 
cases veins have a typical anatomical position and can be 
accessed using simple maneuvers. Moreover, PVs are visu-
alized anyway during contrast injection for determination 
of the balloon occlusion grade. In difficult cases, when one 
of the veins cannot be intubated or there is a need to con-
firm the presence of common trunk or an additional vein is 
suspected, the LA angiography can be performed by a fast 
injection of 50 ml of contrast into the LA during fast ventric-
ular pacing (250 bpm; to slow atrial emptying) – Figure 1.
Once the mapping catheter is inside the target vein, 
the markers on the cryoballoon body are used to position 
it outside of the Flexcath sheath (the second white band 
indicates that the cryoballoon is out of the sheath). Bal-
loon inflation should be performed outside of the vein 
– in the PV antrum or LA. An antral level of isolation likely 
reduces collateral damage by maximizing the distance 
between the balloon and the phrenic nerve, the esoph-
agus and the lungs. It is extremely important to provide 
adequate forward pressure to the balloon/sheath to en-
sure the best possible contact of the balloon with the 
PV antrum. Often appropriate Flexcath rotation/flexion 
or some ‘tricks’ (see below) are necessary for this. Good 
contact ensures rapid isolation and probably prevents 
re-conduction. Initial confirmation of a good contact re-
lies on the assessment of the occlusion grade with con-
trast injection via the balloon catheter lumen into the 
occluded vein. There should be no contrast leak into the 
LA or a very minimal leak that will close once the balloon 
slightly expands during freezing.
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It might be tempting to position the balloon deeper, 
not in the antrum but in the proximal part of the PV, as 
this provides a more stable position, a perfect occlusion 
and a fast isolation. However, it is a very dangerous ap-
proach and cannot be pursued, and once such a position 
is identified, the balloon should be immediately deflat-
ed and repositioned. In large diameter superior veins it 
is especially easy to inadvertently position the balloon 
too deep. To ensure an antral position the ‘proximal seal’ 
technique should be routinely used (Figure 2). This tech-
nique is based on withdrawing the cryoballoon slightly 
to create a temporary contrast leak, as this will either vi-
sualize the PV ostium or will visualize the more proximal 
part of the vein, indicating that that the balloon, after 
withdrawal, was still inside the vein. In such cases a pop-
ular trick that increase the balloon diameter and stiff-
ness and prevents it from jumping inside the PV during 
forward pressure is to initiate the ablation/freeze a few 
seconds before advancing the balloon.
For good vein occlusion and balloon contact with the 
antrum the proper alignment of the axes of the mapping 
catheter, the Flexcath sheath and the PV antrum is prob-
ably the decisive factor. Therefore, if a  good occlusion 
cannot be initially achieved, then the vein should be intu-
bated several times as different branches are then often 
engaged with the mapping catheter and the orientation 
of the Flexcath sheath, with regard to the antrum, as 
well as the sheath and catheter rotation/flexion changes. 
Although most of the support for the balloon is provid-
ed by the Flexcath sheath, the mapping catheter often 
also provides a desirable stabilization – but only when 
positioned deep inside the vein. Unfortunately, this pre-
vents real-time monitoring of the PV isolation process, 
as in a  deep position the catheter does not record PV 
potentials. Therefore, the deep mapping catheter posi-
tion facilitating stabilization versus the shallow position 
facilitating PV potential recording should be balanced. 
We initially aim for recording of PV potentials, as this 
provides the ultimate information that the balloon was 
in good circumferential contact with the tissue and also 
because such technique facilitates avoidance of a  too 
deep position of the balloon. Therefore, once the occlu-
sion is achieved the circular mapping catheter should be 
withdrawn and rotated (‘back-flipped’) so that it rests on 
the balloon and records PV potentials – Figure 3. Only 
when this repeatedly results in instability/leak/balloon 
displacement should a  deeper positioning of the map-
ping catheter be allowed. In such cases instead of the 
real-time PV potentials monitoring, other methods for 
confirmation of PV isolation should be used (see below).
Assessment of the freeze quality and freeze 
dosing
Assessment of proper positioning of the balloon con-
tinues during the freeze application by processing of the 
real time data from the cryoconsole (temperature drop) 
and the circular catheter (disappearance of PV potentials, 
“time to isolation”). Too fast temperature drop (cold-
er than –40°C at 30 s) and too deep nadir temperature 
(colder than –56°C at any time) indicates a dangerously 
deep position of the balloon and the freeze should be 
aborted. As a rule, in such cases a more proximal position 
with proper temperature behavior can be obtained. Too 
slow temperature drop resulting in too high temperature 
at 1 min (warmer than –35°C) should also prompt abor-
tion of the freeze as the balloon is probably in poor con-
tact with the antrum. The thaw time also indicates good 
vs. poor contact, and shallow vs. deep balloon position. 
These phenomena and the proper temperature behavior 
pattern are illustrated in Figure 4.
Short time to isolation is considered the best predic-
tor of a durable lesion and another indicator of a proper 
balloon position. Time to isolation below < 40 s is a very 
good sign, and likely a  single, short (120–150 s) freeze 
per such vein might be enough. Time to isolation < 60 s 
is probably acceptable, while a  longer time to isolation 
or lack of isolation at the end of cryoapplication requires 
a second freeze – after some change of the balloon po-
sition/alignment. The thaw time/rate also informs about 
the balloon position within the antrum/vein (Figure 4) and 
is a marker of a durable lesion. However, most likely none 
of the predictors is good enough to allow the operator 
to be absolutely certain than the vein was permanently 
Figure 1. Left inferior pulmonary vein could not be 
localized and the angiography of left atrium was 
performed with 50 ml of contrast injected via the 
Flexcath sheath during fast ventricular pacing (to 
slow atrial empting); this visualized left common 
trunk and confirmed absence of a separate inferi-
or pulmonary vein
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isolated; therefore, other factors should be considered for 
individualized cryoenergy dosing. Recommended freeze 
time per vein and per application evolved over the years. 
Despite multiple studies comparing various fixed and ti-
trated dosing protocols, this part of the procedure is still 
far from evidence-based standardization. In 2009 we used 
3 freezes of 4–5 min duration per vein; nowadays, often 
a single 120–180 s application is considered enough. Our 
standard protocol is a single 240-second freeze per vein 
for left-sided PVs and a single 180-second application per 
vein for right-sided PVs. These times are often modified 
and additional freezes are often added according to the 
time to isolation, achieved temperature drop, phrenic 
nerve behavior and the perceived arrhythmogenic poten-
tial of a particular vein – Figure 5. When dozing the freeze 
time, several simple rules should be considered. 1). Fast 
temperature drop and a quick isolation is not equivalent 
to slow temperature drop and late vein isolation, even 
if similar temperatures are reached. Slow temperature 
drop probably indicates a small area of balloon contact 
with the antrum and/or constant rewarming and the le-
sion might not be permanent. 2). Increasing freeze time 
in cases with slow temperature drop will increase the risk 
of collateral damage, as with the increased duration of 
the freeze the depth of ice penetration into the nearby 
tissues grows. 3). Bonus freeze is usually not necessary 
when the initial freeze had very good parameters (time 
to isolation < 40 s and the temperature at 1 min below 
–40°C), 4). Evidently poor freeze parameters: time to iso-
lation > 90 s or temperature at 1 min warmer than 35°C 
indicate the need for another freeze. 5). Shorter freeze 
time and no-bonus freeze policy decreases left atrial dwell 
time, while too short freeze time (< 180 s or even below 
240 s for left sided veins) is related to a smaller lesion 
and a higher risk of re-conduction.
Additional positioning techniques
Several ‘tricks’ have been proposed to improve the 
acute results of the cryoballoon based PVI. The most 
common trick used to facilitate the occlusion of the in-
ferior PVs is the hockey stick technique – for this the 
Flexcath sheath should be maximally bent and pushed 
up to provide support for the balloon from the superior 
position in the left atrium (Figures 3 and 6); the map-
ping catheter/guidewire should be placed in the most 
inferior (caudal) branch of the PV, resulting in a  hock-
ey stick figure on the fluoroscopy. If despite the hockey 
stick technique there is still a poor occlusion/tempera-
ture or the vein is not isolated at 40–60 s the pull-down 
maneuver can be used. It is based on the assumption 
that the superior part of the balloon, frozen to the su-
perior aspect of the inferior vein, stabilizes the cathe-
Figure 2. Proximal seal technique. A – A good 
vein occlusion indicated by the contrast retention 
during an apparently proximal balloon position. 
However, instead of initiating the freeze applica-
tion, the balloon was slightly pulled back to cre-
ate a temporary contrast leak. B – During balloon 
withdrawal instead of a contrast leak to the left 
atrium – a more proximal part of the left superior 
pulmonary vein was visualized indicating that the 
balloon was almost completely inside the vein.  
C – The balloon was pulled back more until the cre-
ated contrast leak delineated the antrum and in-
dicted the proper proximal position of the balloon
A B
C
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Figure 3. Left inferior pulmonary vein is occluded with the cryoballoon. Distal position of the circular mapping 
catheter results in lack of pulmonary vein potentials (circle, left panels). After rotation with pulling of the circu-
lar mapping catheter it backflips and rests on the balloon where ample pulmonary vein potentials are recorded 
(right panels)
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Figure 4. Temperature behaviour patterns observed in the same patient during three separate freeze appli-
cations in the right inferior pulmonary vein. The first freeze (A) illustrates rapid temperature drop exceeding 
–40°C at 30 s. This had prompted to stop the application at 1 min when the temperature dropped to –60°C. 
Such rapid temperature drop was caused by positioning the balloon inside the pulmonary vein (D). Note very 
slow re-warming resulting in a long thaw time. After the balloon was repositioned to a more proximal position 
(E), the next freeze resulted in a very sluggish temperature drop that plateaued around –30°C (B). That indi-
cated a poor tissue contact and prompted to stop the freeze to prevent local oedema/temporary lesion; that 
freeze should have been stopped earlier – already at 1 min. The third freeze was performed with the balloon in 
the same proximal/antral position as before (E), albeit with a more forward pressure and strong counterclock-
wise rotation of the Flexcath sheath; this resulted in the optimal balloon position and a good tissue contact 
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ter and pulling the catheter will occlude the vein by 
closing the inferior gap. This maneuver is very effective 
in the acute setting. Often the isolation occurs within 
a  few seconds after pulling the catheter and the tem-
perature curve will show an additional small but abrupt 
decrease. However, the usefulness of the pull-down 
technique is debatable. Some argue that after 40–60 s 
the balloon is already covered with an ice layer and 
cannot provide a good tissue contact at the gap; con-
sequently the isolation will be temporary and the lesion 
not transmural. We do not share that opinion. The pull-
down maneuver has several beneficial effects: 1) it in-
creases the contact area of the cryoballoon at its inferior 
perimeter, 2) increases contact pressure on local tissues 
which decreases warming effects of local blood flow, 
3) closes the gap preventing warming effects of PV blood 
flow. These mechanisms profoundly impact heat trans-
mission (subtraction) and lesion size. We are not aware 
of any studies showing worse outcomes in patients 
treated with the pull-down technique or supporting the 
Figure 5. Electrical activity in the left superior pulmonary vein very suggestive that this vein was the culprit 
vein for paroxysms of atrial fibrillation. Left panel: the spontaneous activity in that vein was much faster than 
in the rest of the left atrium: cycle of 90–100 ms versus 250 ms in the coronary sinus (CS). Right panel: during 
freeze application the spontaneous activity in the vein slowed down and the sinus rhythm was restored. In our 
opinion such a vein deserves a bonus freeze regardless if the initial freeze resulted in a fast isolation or not
A B
Figure 6. When direct approach to the occlusion of the inferior pulmonary veins fails, the hockey stick tech-
nique should be tried. This relies on the strong flexing of the Flexcath sheath to provide support for the balloon 
from the superior position; it is advised to intubate the most inferior (caudal) branch of the pulmonary vein to 
facilitate this approach. The resulting hockey stick figure on the fluoroscopy can be appreciated on the upper 
panel in case of an inferior pulmonary vein occlusion and in the lower panel in a case of a superior pulmonary 
vein occlusion
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speculation that the veins isolated with the pull-down 
technique are not permanently isolated; on the contrary, 
there are studies showing that the pull-down maneu-
ver results in permanent isolation of PVs [8, 9]. More-
over, the reasoning that an ice layer prevents cryoenergy 
transmission seems faulty; thermal conductivity of ice 
is good. The best evidence comes from the cryoablation 
itself – damage to the phrenic nerve or other adjacent 
structures occurs despite the lack of a direct contact with 
the balloon, low temperatures reach the phrenic nerve 
via other frozen tissues – composed mainly of water – 
i.e. via an ice layer. We use the pull-down technique also 
in cases without contrast leak, as in such cases it can 
also result in sudden isolation of the vein, through the 
above-mentioned mechanisms no. 1 and 2. Occasionally 
the gap or narrow area of contact between the balloon 
and the PV antrum is at the superior perimeter of the 
balloon and instead of the pull-down, a push-up maneu-
ver will lead to the increased contact surface area and 
increased tissue compression resulting in fast PV isola-
tion. The overlapping freeze/lesion technique is an alter-
native and complementary technique to the pull-down/
push-up maneuvers. It is applicable especially to cases 
with a  large diameter antrum of a common trunk that 
cannot be proximally occluded with the 28 mm balloon. 
The overlapping freeze applications are performed using 
the Flexcath sheath to obtain a firm contact of the bal-
loon with different parts of the antral perimeter during 
the subsequent freezes. This technique seems inferior to 
the pull-down maneuver as an incomplete PV occlusion 
results in an unbroken blood flow in the vein and tissue 
warming – including at the area of balloon contact.
Thawing and balloon deflation
After completion of the desired freeze time the bal-
loon is automatically deflated when the temperature 
reaches 20°C. However, often the balloon is still frozen 
to the PV/antrum – as demonstrated in Figure 7. Repo-
sitioning the balloon immediately after deflation might 
damage the PV wall; it is recommended to wait until the 
ice cap melts completely. However, often it does not con-
tain contrast and is, therefore, not visible; gentle pulling 
can be used to ensure that the catheter in not adhered 
to tissue but moves freely. Very slow thawing should 
raise the suspicion that the balloon was inside the PV, 
while very fast thawing indicates that the surface area of 
balloon contact with the antrum was small and perhaps 
a bonus freeze with slightly different position should be 
made even if the PV isolation was achieved. When it is 
planned to occlude another vein the balloon should be 
retracted into the sheath; for this the balloon should be 
first inflated and deflated while advancing the push but-
ton on the catheter handle that extends the balloon to 
maximum length. 
Electrophysiological assessment of pulmonary 
vein isolation
Regardless of the energy source used for ablation, 
demonstration of PV isolation is obligatory. Real-time 
Figure 7. Despite automatic deflation of the balloon by the cryoconsole and rewarming to 36°C and, the cath-
eter should not be repositioned because it is still frozen to the pulmonary vein – as evidenced by the residual 
ice plug in the proximal part of the vein. In the left panel the ice completely occludes the vein as evidenced by 
contrast retention. On the right panel with fluoroscopic image obtained some 20 s later, the contrast complete-
ly leaked into the left atrium but the circular mapping catheter is still firmly frozen to the vein
A B
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monitoring of PV potentials and rapid PV isolation ob-
served in the majority of cases makes this task easy 
during CB ablation (Figure 8). This method leaves little 
doubt what the PV potential and the far-field potential 
are, and when block occurs, therefore, additional maneu-
vers are rarely necessary to confirm PV isolation. 
However, when the real-time recording of PV poten-
tials is not feasible, alternative methods have to be used. 
An elegant proof that the vein was isolated is the obser-
vation of a spontaneous PV electrical activity dissociated 
from the atrial activity (Figure 9). However, this is a rela-
tively uncommon phenomenon. Constant pacing from the 
circular mapping catheter during freezing enables one to 
demonstrate the exit block as it will manifest itself with 
delayed activation and then loss of synchronized atrial 
activation while PV capture is ensured by the stable po-
sition of the frozen catheter. Pacing inside the PV with 
5 V output after the ablation and at the site of recorded 
suspicious potentials also differentiates local potentials 
from far-field potentials that are usually not captured 
with moderate/low output. Alternatively, the template 
method can be used by obtaining a proximal recording of 
the PV potentials before the freeze and comparing it with 
the recordings from the same position obtained after the 
freeze. In the case of doubt, if the remaining potentials 
are far-field or PV potentials classic electrophysiological 
maneuvers should be performed using the coronary si-
nus catheter and the His bundle catheter for right atrial, 
CS and left appendage pacing for differentiation.
Extended use of cryoballoon catheter for 
ablation/isolation of non-PV targets
Pulmonary vein isolation is the cornerstone of the AF 
ablation procedure, but outcome benefits of ablation of 
other targets are less well documented or controversial. 
However, in selected patients ablation of non-PV sites 
might be critical to achieve a good outcome. Cryoballoon 
can be used (off-label) to isolate the superior vena cava 
and the persistent left superior vena cava using a similar 
approach as with pulmonary veins [10]. Extreme caution 
should be used in such cases as the risks of such use of 
the cryoballoon are not defined and vein stenosis and 
damage to left the phrenic nerve, the sinus node or other 
structures are quite possible. The left atrial appendage 
can also be the source of AF triggers, and CB based isola-
tion of the left atrial appendage was reported to improve 
the outcome [11]. Potentially, CB based ablation might 
be a better option for such procedures than the point-by 
Figure 8. Cryoballoon based isolation of the left inferior pulmonary vein during a re-do procedure in a patient 
after remote point-by-point RF pulmonary vein isolation. Real time recording of the pulmonary vein potentials 
allow easy differentiation of PV potentials and far-field potentials
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point RF technique. However, undefined risk of damage 
to the right phrenic nerve, coronary arteries, appendage 
perforation and mechanical dysfunction of the isolated 
appendage, with related thromboembolic risk, makes 
this procedure controversial and justified only in highly 
selected cases with evident triggers in that structure. It 
was recently shown that the cryoballoon can be used for 
isolation of the posterior wall and the creation of a roof 
line [12]. Such a  procedure is technically challenging, 
time consuming and potentially related to the increased 
risk of damage to the esophagus and creation of an atrio-
esophageal fistula. Until further studies characterize the 
outcome benefits and safety of such an approach it can-
not be recommend for routine use.
Post-procedural management 
Immediately after the procedure we routinely per-
form a short echocardiographic study, still in the electro-
physiological laboratory, to exclude pericardial effusion. 
If there is substantial effusion, regardless of symptoms, 
pericardiocentesis is not deferred but immediately per-
formed. Post-procedural groin management depends on 
the results of the echocardiographic examination. If there 
is any trace of pericardial effusion, or the transseptal 
puncture was troublesome, protamine is administered, 
the sheaths are removed and a figure-of-eight suture is 
used to stop the bleeding. If the result of the echocardio-
graphic examination is normal then the sheaths are left 
and removed on the ward after 5 h. Oral anticoagulation 
is either normally continued or if the morning dose was 
skipped then it is administered 5 h after obtaining groin 
hemostasis. Long-term anticoagulation is always con-
tinued for 2 months, regardless of the presence of risk 
factors for stroke, although probably one month should 
suffice as the healing process is at that time already 
completed. Necessity of a long-term continuation of an-
ticoagulation should be determined on the basis of the 
patient’s stroke risk profile and not on the apparent suc-
cess or failure of the ablation procedure. Preprocedural 
antiarrhythmic drugs are usually continued for 3 months 
of the so-called blanking period. In patients with long-
term persistent atrial fibrillation and/or heart failure, 
occasionally amiodarone is continued for 6 months to 
facilitate atrial remodeling. Monitoring for AF recurrence 
is based on symptoms, periodic ECG monitoring, Holter 
ECG monitoring (every 6–12 months) and occasionally 
by implantable ECG recorders – Figure 10 [13]. It is well 
documented that the success rate defined according to 
the guidelines-recommended detection of a  30-second 
long AF episode depends on the intensity of ECG mon-
itoring – to the point when after the implantation of the 
continuous ECG recorder it loses its original sense and 
other measures of success have to be applied (AF burden 
rather than the 30-second AF episode detection). Howev-
er, since the procedure is mainly performed for control of 
symptoms, extensive search for asymptomatic episodes 
of AF has undefined practical value. 
Acute and long-term outcome
Several studies and metanalyses have assessed the 
acute and long-term efficacy of cryoballoon-based PVI. 
The reported success rate of PV isolation during the pro-
cedure is about 98% [14, 15]. Despite this, the long-term 
effectiveness of the procedure (AF free survival) assessed 
at one year after the ablation is in the range of 70–82%. 
The AF-free survival rate significantly depends on the clin-
ical characteristics of the studied group and the presence 
of risk factors, especially the type of AF – paroxysmal vs. 
Figure 9. Electrical isolation of the left inferior pulmonary vein was diagnosed by observation of an exit block – 
there was a spontaneous slow electrical activity in the pulmonary vein (Las2 - Las4) that was dissociated from 
the regular electrical atrial activity and the sinus rhythm, evident in the coronary sinus recordings (CS1-CS2) 
and the surface ECG leads (III, aVR, aVF, V1), respectively
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persistent, LA size and the presence of heart failure [15, 
16]. Patients with persistent AF have a poorer long-term 
outcome than patients with paroxysmal AF – 55–72% 
vs. 75–81% respectively [15, 17, 18]. Patients with heart 
failure probably have the greatest survival benefit from 
AF ablation (CASTLE-AF trial) despite the significantly 
lower AF-free survival after ablation than patients with 
preserved left ventricular function [19–22]. In our cen-
ter we observed similar efficacy of ablation with almost 
80% of patients without recurrence at 1 year. Type of AF 
and LA size were the strongest predictors of failure in our 
population [23].
Both CB and RF ablation techniques are considered 
as standard methods with similar outcomes. However, 
based on the largest comparison of both techniques – the 
“Fire and Ice study” – patients after CB ablation had sig-
nificantly fewer all-cause re-hospitalizations, cardiovas-
cular re-hospitalizations, re-ablations, and direct current 
cardioversions after the index procedure [2, 16, 24, 25]. 
In our opinion there are several important advantages 
of CB ablation making it the preferred approach. During 
CB ablation a more stable position of the catheter can be 
achieved, which is less sensitive for beat-to-beat heart 
and respiratory motions. With CB there is better control 
over application, which translates to more predictable, 
more continuous and homogeneous lesions, that are less 
arrhythmogenic. The rate of secondary, iatrogenic LA ar-
rhythmias after cryoballoon ablation is markedly lower 
than after the point-by-point RF technique (very high for 
inexperienced operators, non-negligible for experienced 
operators). The PV re-connection rate after CB ablation is 
dramatically lower than after RF ablation. The most strik-
ing difference that makes the CB ablation the method of 
choice for many operators is the speed of PV isolation; it 
usually takes less than 1 min from the balloon apposition 
in the antrum to the electrophysiologically confirmed PV 
isolation, and this translates into a much shorter LA dwell 
time, usually < 30 min. In contrast to RF ablation there is 
usually little doubt whether PV was isolated or not. Gener-
al anesthesia during ablation is not necessary as the pro-
cedure is less painful than the RF ablation.
Adverse events and prevention of phrenic 
nerve injury 
Prospective, registry-based data show that approx-
imately 4–14% of patients undergoing AF catheter ab-
lation experience complications, 2–3% of which are 
serious/potentially life-threatening. The frequency of 
complications after CB ablation is similar, however, it dif-
fers to some extent between studies – Table I  [26–30]. 
Based on the large clinical trials, in which mainly expe-
rienced high-volume centers take part, major compli-
cations occur in approximately 4.0% of patients; this is 
similar to data coming from our center. Complications 
occur mostly within the first 24 h after the ablation. The 
spectrum of complications includes hematoma and/or 
Figure 10. Implantable ECG recorder enables to monitor effect of cryoballoon ablation in a much more accurate 
fashion than the periodic ECG monitoring. Several AF episodes (blue bars) were confirmed before the pulmo-
nary vein isolation (red arrow); while after the procedure there was only one AF episode – during the healing 
phase/blanking period. That confirmed the good result of the procedure
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Death 0 2 (0.09) 1 (0.18) 0 0 0
Pericardial effusion needed 
treatment
1 (0.43) 6 (0.27) 0 1 (0.27) 2 (1.28) 5 (0.85)
Pericarditis 3 (1.29) 4 (0.18) N/D N/D N/D 1 (0.17)
Stroke 1 (0.43) 4 (0.18) 1 (0.18) 2 (0.54) 0 1 (0.17)
Transient ischemic attack 2 (0.86) 0 1 (0.18) 0 0 1 (0.17)
Major groin complication 1 (0.43) 10 (0.9) 3 (0.54) 7 (1.89) 6 (3.84) 9 (1.53)
Persistent* phrenic nerve 
palsy
3 (1.29) 22 (0.99) 15 (2.7) 10 (2.7) 5 (3.2) 7 (1.17)
Permanent phrenic nerve 
palsy
0 8 (0.36) 3 (0.54) 1 (0.27) 0 1 (0.17)
Atrioesophageal fistula 0 0 0 0 0 0
Pulmonary vein  stenosis 0 0 0 0 0 0
ASD requiring intervention N/D N/D N/D N/D N/D 8 (1.36)
Numbers in parentheses denote percentage; *persistent indicates present after discharge; ASD – atrial septal defect.
pseudoaneurysm at the groin access site, cardiac tam-
ponade/pericardial effusion, thromboembolism causing 
cerebrovascular accidents, phrenic nerve injury/palsy, 
migraine attacks, silent cerebral lesions, hemoptysis, per-
iesophageal vagal nerve injury/gastroparesis, pericarditis 
and iatrogenic atrial septal defect. 
The periprocedural death rate related to AF abla-
tion is approximately 0.2–0.98%; however, in the major-
ity of CB studies and in our practice no deaths were ob-
served [31]. The most common (1–0.5%) life-threatening 
complication is tamponade [32]. Pulmonary vein stenosis 
and atrioesophageal fistula formation are complications 
occurring mainly after RF ablation, hardly ever after CB 
ablation [33]. We believe that monitoring temperature in 
the esophagus, recommended by some to prevent atrio-
esophageal fistula formation, is not justified. Frequency 
of this complications after CB based ablation (1 : 10 000) 
is 10 times lower than after RF ablation (1 : 1000), and 
likely mostly related to positioning the CB deep within 
the left inferior PV [34]. Routine prescription of proton 
pump inhibitors to facilitate healing of esophageal inju-
ry/prevent fistula formation, recommended by some, has 
unproven value. The practice of stopping the freeze when 
the temperature drops below –56°C, limiting the time 
and number of freezes and following the proximal seal 
technique probably further reduces this complication.
The complication most feared by the patients is 
stroke. Over 11 years of performing this procedure we 
have observed only one such incident (0.17%), in which 
symptoms largely resolved during follow-up, and one 
short-lasting transient ischemic attack; this was much 
less than the stroke rate reported for the RF-based AF 
ablation procedures (approx. 1%). However, according to 
the literature silent cerebral embolization, a  phenome-
non of unknown clinical significance, occurs in approxi-
mately 25% of patients – similarly as in many other car-
diac interventions that involve left heart catheterization. 
Most likely the cerebral embolization is mainly related 
to air embolism. Great care is mandatory during sheath 
management; catheter insertion and withdrawal should 
be slow to avoid air suction via the Flexcath valve, and 
reinsertion of the CB catheter should be avoided.
Pericarditis develops in a very small percentage of pa-
tients after cryoablation ablation – probably due to a larg-
er than usual surface of the transmural lesions. The long-
term consequence of subclinical pericarditis (Figure 11), 
probably an underestimated phenomenon, could be the 
formation of pericardial adhesions [35]. Hemodynami-
cally important iatrogenic atrial septal defect (ASD) and 
its consequences after PVI seem to be an underestimat-
ed problem as well. There are limited data from the litera-
ture regarding this complication [36]; the large diameter 
of the Flexcath sheath that facilitates this complication 
is one of the weak sides of the current technology. Apart 
from many cases of asymptomatic, tiny ASD and a few 
cases of ASD requiring percutaneous intervention, we 
have observed a few cases of severe migraine after CB 
ablation, a  complication probably related to iatrogenic 
ASD. In some patients this was de novo migraine, but 
in most cases it was an exacerbation of the pre-existing 
migraine that was inactive before the procedure, some-
times for many years. In all our cases migraine subsided 
within a  few months. The estimated incidence of mi-
graine after ablation/transseptal puncture is 1–2% [37].
Palsy of the right phrenic nerve deserves special at-
tention as it remains the Achilles’ heel of the cryoballoon 
technique (Figure 12). It usually occurs during freezing in 
the right superior PV, less frequently in the right inferior 
PV. It is the most common intraprocedural complication, 
occurring in about 8–6% of patients; although it usually 
resolves within a few minutes it limits further freeze de-
livery to the right PVs. Persistent palsy (i.e. still present 
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at discharge) is present in approximately 1–2% of cas-
es [38]. Steroids might be administered in such cases to 
limit inflammation. In most of these cases the phrenic 
nerve regains function within 1 year. Permanent nerve 
palsy affects approximately 0.2% of cases, fortunately, 
most of them remain asymptomatic. A chest X-ray is rec-
ommended before the discharge in cases where phrenic 
nerve palsy was observed during the procedure. In some 
patients phrenic nerve palsy might course under the 
mask of pneumonia/atelectasis. 
Several precautions can limit this complication sig-
nificantly. During every freeze in the right sided PVs the 
phrenic nerve activity must be monitored by constant 
pacing. The left phrenic nerve can be paced by placing 
the coronary sinus deflectable catheter near the junc-
tion of the superior vena cava and the right subclavian 
Figure 11. 12-lead ECG recorded at the beginning (panels ‘PRE’) and at the end (panels ‘POST’) of an uneventful 
cryoballoon ablation procedure. After the procedure there is an evident depression of the PR interval in several 
leads (II, III, aVF, V1-V3) as well PR interval elevation in lead aVR indicating pericardial inflammation due to 
the transmurality of the cryoablation lesions – or more extensive necrosis/damage to the left atrium. This is 
a common ECG phenomenon post cryoballoon ablation
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vein. Phrenic nerve function is then monitored by con-
stant palpation of the abdomen. At the first moment 
when the strength of the diaphragmatic excursion de-
creases, the balloon should be deflated using the double 
stop technique (resulting in immediate deflation rather 
than delayed deflation occurring when the balloon is re-
warmed). Some recommend monitoring the diaphrag-
matic compound motor action potential [39]. This can be 
easily done by observing ECG with modified lead I: the 
right-arm electrode is placed above the xiphoid, and the 
left-arm ECG electrode is placed along the right costal 
margin. This methods also allows the other members of 
the team to monitor the nerve function in the electro-
physiological laboratory and, according to a few studies, 
makes it possible to detect the damage to the phrenic 
nerve at a  slightly earlier phase than monitoring me-
chanical function. We ceased to use this method as in 
our experience it does not offer any advantage over man-
ual palpation; a noticeable decrease in the potential am-
plitude seems to be coincident with the decrease in dia-
phragmatic excursion. Apart from monitoring the nerve 
function it is important to position the balloon in the PV 
as proximally as possible, not allowing too low tempera-
tures, and occasionally use the ‘pull-back’ maneuver.
Conclusions
Cryoballoon technology greatly simplified the con-
temporary approach to the PV isolation procedure, with-
out compromising outcomes, offering a  new hope for 
patients with AF. For a safe and effective procedure the 
electrophysiologist/interventionalist should be aware 
of all minute details of the procedure including several 
tricks developed by the most experienced operators and 
the pre-procedural and post-procedural management 
recommendations. Detailed knowledge of complications 
of CB-based ablation is mandatory.
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